|
|
Post by biposter on May 30, 2019 18:29:53 GMT
investor.bluebirdbio.com/static-files/49bca517-85ca-4b4c-8f0f-26bebc3a5e0c Anybody like $BLUE? It’s been a long road for them, but they should finally get their first gene therapy, Lentiglobin for beta-thalassemia, approved in the EU next month. If so, it will be first commercial gene therapy to treat b-thalassemia. They expect to file in the U.S. by eoy and gain approval in 2020. Plus, data readout on their multiple myeloma CAR-T therapy by eoy and potential U.S. approval in 2020. Then a CALD approval in 2021 and a sickle cell disease approval in 2022 (if data is good, of course). So a deep pipeline. COH: $1.9B at end of 2018, and cash runway into 2022. KITE and JUNO got bought out a while back, but BLUE is still a standalone company. Maybe will be taken out after their first approval in the EU?
|
|
|
|
Post by lcd on May 30, 2019 22:33:32 GMT
I haven't ever owned $BLUE but when I saw your post I went back into my watchlist and see that I started following them in September 2016 because they were recommended by Kiplinger in the mid-50s. Been one big up then some downs since then.
|
|
|
|
Post by biposter on May 31, 2019 17:43:34 GMT
Yeah, lcd, I remember Brad Loncar’s $BLUE pps poll back in 2015, I believe. And the stock popped to $210(?). If approved, we’ll see how the market responds, since b-thal isn’t as big a market as sickle cell, which is years away. Looks like $GBT will file an NDA for sickle cell later this year and commercialize in 2020. They’re going to release data in June. Still, I like BLUE as long-term hold. But my wag is a buyout by eoy.
|
|
|
|
Post by biposter on Jun 3, 2019 18:01:34 GMT
BLUE got EU approval for beta-thalassemia. Not much of a market response. Not sure of the EU #s, but for comparison, there are about 100,000 sickle cell vs a few thousand b-thal patients in the U.S. $GBT will file their NDA in H2 for sickle cell. But theirs is a once-daily oral med. BLUE should get sickle cell disease approval in 2022, and it’s a one-and-done gene therapy. BLUE will price its Tx next week. Could be more political fireworks like NVS’ $2.1mln “most expensive drug on market” headlines last week. Hopefully BLUE’s is cheaper lol.
|
|
